The Nifty index sell-off indicates it’s still a sell-on-rise scenario, with immediate resistance at 23,100 and support at 22,850. Momentum indicators remain below oversold levels, suggesting a potential dead cat bounce. Options data for January expiry shows increased put writing at 23,000 and above, signalling support, according to Praveen Dwarakanath of Hedged.in.
Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25
Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected
January 30, 2025